Natrecor (nesiritide) July 2005
Audience: Cardiologists/cardiovascular healthcare professionals
[Posted 07/18/2005] Scios and FDA notified healthcare professionals about the recommendations of an expert panel of cardiology and heart failure clinicians with regard to NATRECOR (nesiritide). With respect to recent questions raised about worsened renal function and mortality, the panel provided a consensus statement on each issue, provided advice on the ongoing and planned clinical development program, made recommendations about the appropriate use of the drug and recommended an educational campaign to ensure that clinicians understand when the use of NATRECOR is appropriate and when it is not appropriate.
[July 13, 2005 - Letter - Scios]